Campfield Therapeutics

Founded in 2026 and headquartered in San Diego, US, Campfield is cofounded by David Socks(COO). Campfield Therapeutics specializes in innovative therapeutic solutions for inflammatory diseases. The company was established to develop its flagship product, Prifemilast, as part of its initial business strategy. Their flagship product, Prifemilast, is a once-daily oral PDE4B-selective inhibitor designed to enhance cAMP signaling in immune cells, thereby reducing inflammation associated with conditions such as ulcerative colitis and Crohn's disease. This investigational therapy has demonstrated robust efficacy and a favorable tolerability profile in over 700 clinical trial participants, including notable results from a Phase 3 trial in plaque psoriasis. The company aims to address significant unmet needs in the IBD treatment landscape by offering a more convenient and effective therapeutic option compared to currently available treatments, which are often limited by poor tolerability and safety concerns. Prifemilast is being developed for global markets, with clinical trials currently underway in North America and other international regions. Revenue generation is anticipated through partnerships and collaborations, particularly with biopharmaceutical firms such as Newsoara Biopharma, which is developing Prifemilast for the Greater China market. The company’s business model includes B2B partnerships with healthcare providers and institutions, focusing on the distribution of their oral therapies to patients requiring effective IBD treatments. While precise pricing plans have not been disclosed, transactions will primarily occur through negotiated agreements with healthcare systems and possibly insurance providers. In June 2026, Campfield Therapeutics, Inc. The company plans to expand its clinical trials for Prifemilast into additional global markets, with a focus on North America and other regions as trials progress.

1. Series A

   Jun 19, 2026

   Amount

   $180M

   Investors

   Locked